Stock comparison
Ligand Pharmaceuticals
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LGND
Ligand Pharmaceuticals
Market cap
$4.6B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LGND | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 55D | 77B | LMAT |
| Benjamin Graham | 67D | 89A | LMAT |
| Philip Fisher | 64C | 81C | LMAT |
| Peter Lynch | 54C | 67B | LMAT |
| Joel Greenblatt | 53D | 56D | LMAT |
| Charlie Munger | 57D | 68D | LMAT |
| Terry Smith | 47D | 69D | LMAT |
Side-by-side metrics
| Metric | LGND | LMAT |
|---|---|---|
| Market cap | $4.6B | $2.23B |
| P/E (TTM) | 27.6x | 37.1x |
| EV/EBIT | 97.7x | 36.6x |
| ROIC (TTM) | 5.61% | 9.43% |
| Gross margin | 98.61% | 72.39% |
| Net margin | 55.95% | 24.35% |
| Revenue CAGR 5y | 2.64% | 12.75% |
| EPS CAGR 5y | 16.8% | 19.04% |
| Debt / Equity | 0.5x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LGND leads on
- Net margin55.95%vs 24.35%+56%
- Market cap$4.6Bvs $2.23B+51%
- Gross margin98.61%vs 72.39%+27%
- P/E (TTM)27.6xvs 37.1x+26%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Revenue CAGR 5y12.75%vs 2.64%+79%
- EV/EBIT36.6xvs 97.7x+63%
- ROIC (TTM)9.43%vs 5.61%+41%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.